Glembatumumab vedotin

Drug Profile

Glembatumumab vedotin

Alternative Names: CDX-011; CR 011 ADC; CR 011-vcMMAE; CR011; Glemba; Glembatumumab; GV

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CuraGen Corporation
  • Developer Celldex Therapeutics Inc; National Cancer Institute (USA)
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Malignant melanoma; Osteosarcoma; Uveal melanoma
  • Phase I/II Squamous cell cancer
  • Discontinued Brain cancer

Most Recent Events

  • 23 Aug 2017 Celldex Therapeutics completes enrolment in the phase IIb METRIC trial for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Belgium, Canada, Germany, Italy, France, Spain and United Kingdom (NCT01997333)
  • 05 Jun 2017 Efficacy and adverse events data from a phase II trial in Malignant melanoma released by Celldex Therapeutics
  • 28 Feb 2017 Celldex Therapeutics initiates an expanded access of glembatumumab vedotin for Breast cancer (Metastatic disease) (NCT03067935)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top